NYSE:PLX Protalix BioTherapeutics (PLX) Stock Price, News & Analysis $1.54 +0.07 (+4.39%) As of 01:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Protalix BioTherapeutics Stock (NYSE:PLX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get PLX alerts:Sign Up Key Stats Today's Range$1.50▼$1.5650-Day Range$1.35▼$1.6052-Week Range$0.82▼$3.10Volume299,451 shsAverage Volume849,272 shsMarket Capitalization$122.99 millionP/E RatioN/ADividend YieldN/APrice Target$15.00Consensus RatingBuy Company Overview Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd. Read More Protalix BioTherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScorePLX MarketRank™: Protalix BioTherapeutics scored higher than 49% of companies evaluated by MarketBeat, and ranked 565th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingProtalix BioTherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageProtalix BioTherapeutics has received no research coverage in the past 90 days.Read more about Protalix BioTherapeutics' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth3,000.00% Earnings GrowthEarnings for Protalix BioTherapeutics are expected to grow by 3,000.00% in the coming year, from $0.01 to $0.31 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Protalix BioTherapeutics is -11.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Protalix BioTherapeutics is -11.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProtalix BioTherapeutics has a P/B Ratio of 3.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.18% of the outstanding shares of Protalix BioTherapeutics have been sold short.Short Interest Ratio / Days to CoverProtalix BioTherapeutics has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Protalix BioTherapeutics has recently increased by 1.83%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProtalix BioTherapeutics does not currently pay a dividend.Dividend GrowthProtalix BioTherapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.18% of the outstanding shares of Protalix BioTherapeutics have been sold short.Short Interest Ratio / Days to CoverProtalix BioTherapeutics has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Protalix BioTherapeutics has recently increased by 1.83%, indicating that investor sentiment is decreasing. News and Social Media0.6 / 5News SentimentN/A News SentimentProtalix BioTherapeutics has a news sentiment score of -0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Protalix BioTherapeutics this week, compared to 1 article on an average week.Search InterestOnly 5 people have searched for PLX on MarketBeat in the last 30 days. This is a decrease of -58% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Protalix BioTherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Protalix BioTherapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.50% of the stock of Protalix BioTherapeutics is held by insiders.Percentage Held by InstitutionsOnly 16.53% of the stock of Protalix BioTherapeutics is held by institutions.Read more about Protalix BioTherapeutics' insider trading history. Receive PLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Protalix BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PLX Stock News HeadlinesProtalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 20251 hour ago | prnewswire.comProtalix Lawsuit Dismissed After Bylaws AmendmentAugust 1, 2025 | tipranks.comWashington Thinks They Own Your Bank AccountWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.August 7 at 2:00 AM | Priority Gold (Ad)Protalix BioTherapeutics Names Gilad Mamlok Chief Financial OfficerJuly 21, 2025 | marketwatch.comProtalix Biotherapeutics Inc.: Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial OfficerJuly 21, 2025 | finanznachrichten.deProtalix BioTherapeutics welcomes new finance chiefJuly 21, 2025 | proactiveinvestors.comPLX | Protalix BioTherapeutics Inc. Annual Cash Flow Statement ...July 10, 2025 | marketwatch.comProtalix BioTherapeutics joins Russell 3000 and 2000 indexes following annual reconstitutionJune 30, 2025 | proactiveinvestors.comSee More Headlines PLX Stock Analysis - Frequently Asked Questions How have PLX shares performed this year? Protalix BioTherapeutics' stock was trading at $1.88 at the beginning of the year. Since then, PLX stock has decreased by 17.4% and is now trading at $1.5530. How were Protalix BioTherapeutics' earnings last quarter? Protalix BioTherapeutics, Inc. (NYSE:PLX) released its earnings results on Friday, May, 9th. The company reported ($0.05) EPS for the quarter. Protalix BioTherapeutics had a negative net margin of 21.03% and a negative trailing twelve-month return on equity of 30.89%. When did Protalix BioTherapeutics' stock split? Shares of Protalix BioTherapeutics reverse split on Friday, December 20th 2019.The 1-10 reverse split was announced on Monday, December 9th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 19th 2019. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Protalix BioTherapeutics' major shareholders? Protalix BioTherapeutics' top institutional shareholders include Connor Clark & Lunn Investment Management Ltd. (0.62%), Orin Green Financial LLC (0.08%) and Harel Insurance Investments & Financial Services Ltd. (0.03%). Insiders that own company stock include Aharon Schwartz and Dror Bashan. View institutional ownership trends. How do I buy shares of Protalix BioTherapeutics? Shares of PLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Protalix BioTherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Protalix BioTherapeutics investors own include Brainstorm Cell Therapeutics (BCLI), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Walmart (WMT) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings5/09/2025Today8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNYSE:PLX CIK1006281 Webwww.protalix.com Phone201-696-9345Fax972-4988-9489Employees200Year FoundedN/APrice Target and Rating Average Price Target for Protalix BioTherapeutics$15.00 High Price Target$15.00 Low Price Target$15.00 Potential Upside/Downside+913.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)$0.04 Trailing P/E RatioN/A Forward P/E Ratio148.00 P/E GrowthN/ANet Income$8.31 million Net Margins-21.03% Pretax Margin-21.00% Return on Equity-30.89% Return on Assets-11.74% Debt Debt-to-Equity RatioN/A Current Ratio1.98 Quick Ratio1.27 Sales & Book Value Annual Sales$59.76 million Price / Sales1.97 Cash Flow$0.08 per share Price / Cash Flow17.80 Book Value$0.47 per share Price / Book3.15Miscellaneous Outstanding Shares79,607,000Free Float68,995,000Market Cap$117.82 million OptionableOptionable Beta-0.21 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NYSE:PLX) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredWall Street Hates This Gold IRA Strategy—Here’s WhyWhat if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...Advantage Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protalix BioTherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protalix BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.